OrthoPediatrics posts record FY2025 revenue $236.1M (+15% YoY); guides FY2026 revenue $262-266M

ORTHOPEDIATRICS CORP

2025-FY EPS reported -$1.69 revenue$236,348,000

Q4 2025 revenue $61.3M (+16% YoY); domestic $48.4M (+13%), international $12.9M (+32%).
FY2025 free cash flow usage over 50% lower than FY2024; Q4 FCF $6-7M.
FY2026 revenue guidance $262-266M (11–13% growth); expects ~$25M Adjusted EBITDA.
Received EUMDR certification for Response Spine and trauma/deformity implants.
Helped 37,500 children in Q4; nearly 1.3 million since inception.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.